AlphaMadera's AlphaVal page computes AngioDynamics, Inc.'s fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag ANGO as undervalued, fairly valued, or overvalued.

What is AngioDynamics, Inc.'s fair value?

Fair value for ANGO is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value ANGO?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from ANGO's most recent reported fundamentals.

ANGO - AngioDynamics, Inc.

Price: -- -- | CONSENSUS: Hold DETAILS | PRICE TARGET: $16.50 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

AlphaVal Unavailable

AlphaVal: ANGO has had negative net income and negative EPS in all 5 available fiscal year(s). Quality gate: persistently unprofitable companies are excluded.